Clinical Trials for Dexamethasone

9 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TreatmentVICCHEM1274
03/31/2014
A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
TreatmentVICCHEM1377
03/14/2014
A Phase 1 Study of Arry-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
TreatmentVICCHEM1319
08/07/2013
A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
TreatmentVICCHEM12107
03/31/2013
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)
TreatmentVICCHEM1146
08/14/2012
Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma
TreatmentVICCPED1186
06/11/2012
CA180-372 / AALL1122 - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib (IND# 66, 971) Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
TreatmentCOGAALL1131
04/05/2012
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum
TreatmentECOGHEME2906
01/20/2012
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years)
TreatmentVICCBMT1020
11/15/2010
Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment with Velcade Based Therapy

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.